Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by the variola virus. Its products target orthopoxvirus infections i... SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by the variola virus. Its products target orthopoxvirus infections including smallpox. Mehr anzeigen
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study...
Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectivelyReceived $122 Million of Procurement Orders from the U.S. Government in the...
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.43 | -6.80379746835 | 6.32 | 6.43 | 5.615 | 571415 | 6.03585899 | CS |
| 4 | -0.51 | -7.96875 | 6.4 | 7.555 | 5.615 | 557506 | 6.60845125 | CS |
| 12 | -1.12 | -15.9771754636 | 7.01 | 7.97 | 5.615 | 507343 | 6.77757334 | CS |
| 26 | -0.47 | -7.38993710692 | 6.36 | 12.83 | 5.615 | 961830 | 8.86674106 | CS |
| 52 | 0.28 | 4.99108734403 | 5.61 | 12.83 | 4.26 | 832718 | 8.31493668 | CS |
| 156 | -1.43 | -19.5355191257 | 7.32 | 26.99 | 4.215 | 2207180 | 12.72290321 | CS |
| 260 | 1.24 | 26.6666666667 | 4.65 | 26.99 | 3.96 | 1426501 | 12.24570702 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
